To include your compound in the COVID-19 Resource Center, submit it here.

Daiichi's pexidartinib passes Phase III test in TGCT

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said oral pexidartinib (PLX3397) met the primary endpoint of reducing tumor

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE